W. de Souza

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?

Thais F. C. Fraga-Silva, S. Zorzella-Pezavento, A. Sartori, 2022, Neural regeneration research.